Capital Markets increased its price target on Perspective Therapeutics Inc (NYSE:CATX) shares to $20.00, up from the previous $15.00, while maintaining a Buy rating on the stock. The $259.2 million ...
In a report released today, Nicole Germino from Truist Financial maintained a Buy rating on Perspective Therapeutics (CATX – Research Report).
Wedbush reissued their outperform rating on shares of Perspective Therapeutics (NYSE:CATX – Free Report) in a report released ...
Perspective Therapeutics shares interim results for [212Pb]VMT-α-NET trial, showing promising safety, stable disease cases, ...
JonesResearch analyst Justin Walsh views the selloff in shares Perspective Therapeutics (CATX) yesterday after the company reported initial results from its ongoing Phase I/IIa trial of Pb-212-VMT ...
SEATTLE, Jan. 22, 2025 (GLOBE NEWSWIRE) -- ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers through ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback